Already a Bloomberg.com user?
Sign in with the same account.
GlaxoSmithKline Plc raised its hostile takeover offer for Human Genome Sciences Inc. to about $14 a share, Reuters reported, citing two people familiar with the situation.
On Air Now
Countdown Watch Now
Next
On The Move